Literature DB >> 25296759

Long term expression of Drosophila melanogaster nucleoside kinase in thymidine kinase 2-deficient mice with no lethal effects caused by nucleotide pool imbalances.

Shuba Krishnan1, João A Paredes1, Xiaoshan Zhou1, Raoul V Kuiper2, Kjell Hultenby2, Sophie Curbo1, Anna Karlsson3.   

Abstract

Mitochondrial DNA depletion caused by thymidine kinase 2 (TK2) deficiency can be compensated by a nucleoside kinase from Drosophila melanogaster (Dm-dNK) in mice. We show that transgene expression of Dm-dNK in Tk2 knock-out (Tk2(-/-)) mice extended the life span of Tk2(-/-) mice from 3 weeks to at least 20 months. The Dm-dNK(+/-)Tk2(-/-) mice maintained normal mitochondrial DNA levels throughout the observation time. A significant difference in total body weight due to the reduction of subcutaneous and visceral fat in the Dm-dNK(+/-)Tk2(-/-) mice was the only visible difference compared with control mice. This indicates an effect on fat metabolism mediated through residual Tk2 deficiency because Dm-dNK expression was low in both liver and fat tissues. Dm-dNK expression led to increased dNTP pools and an increase in the catabolism of purine and pyrimidine nucleotides but these alterations did not apparently affect the mice during the 20 months of observation. In conclusion, Dm-dNK expression in the cell nucleus expanded the total dNTP pools to levels required for efficient mitochondrial DNA synthesis, thereby compensated the Tk2 deficiency, during a normal life span of the mice. The Dm-dNK(+/-) mouse serves as a model for nucleoside gene or enzyme substitutions, nucleotide imbalances, and dNTP alterations in different tissues.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Gene Therapy; Mitochondrial DNA (mtDNA); Mitochondrial Disease; Nucleoside/Nucleotide Metabolism; Nucleoside/Nucleotide Transport; Thymidine Kinase 2

Mesh:

Substances:

Year:  2014        PMID: 25296759      PMCID: PMC4239632          DOI: 10.1074/jbc.M114.588921

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers.

Authors:  P A Sherman; J A Fyfe
Journal:  Anal Biochem       Date:  1989-08-01       Impact factor: 3.365

2.  The cytomegalovirus enhancer: a pan-active control element in transgenic mice.

Authors:  E V Schmidt; G Christoph; R Zeller; P Leder
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

3.  Four deoxynucleoside kinase activities from Drosophila melanogaster are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase.

Authors:  B Munch-Petersen; J Piskur; L Sondergaard
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

4.  Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy.

Authors:  A Saada; A Shaag; H Mandel; Y Nevo; S Eriksson; O Elpeleg
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

Review 5.  Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase: overview, genetic heterogeneity and therapy.

Authors:  R Hirschhorn
Journal:  Birth Defects Orig Artic Ser       Date:  1983

6.  Cytosolic high K(m) 5'-nucleotidase and 5'(3')-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism.

Authors:  C Gazziola; P Ferraro; M Moras; P Reichard; V Bianchi
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

7.  Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice.

Authors:  Misako Haraguchi; Hiroaki Tsujimoto; Masakazu Fukushima; Itsuro Higuchi; Hideto Kuribayashi; Hideo Utsumi; Atsuo Nakayama; Yoshio Hashizume; Junko Hirato; Hiroki Yoshida; Hiromitsu Hara; Shinjiro Hamano; Hiroaki Kawaguchi; Tatsuhiko Furukawa; Kohei Miyazono; Fuyuki Ishikawa; Hideo Toyoshima; Tadashi Kaname; Masaharu Komatsu; Zhe-Sheng Chen; Takenari Gotanda; Tokushi Tachiwada; Tomoyuki Sumizawa; Kazutaka Miyadera; Mitsuhiro Osame; Hiroki Yoshida; Tetsuo Noda; Yuji Yamada; Shin-ichi Akiyama
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Kinetic properties of mutant human thymidine kinase 2 suggest a mechanism for mitochondrial DNA depletion myopathy.

Authors:  Liya Wang; Ann Saada; Staffan Eriksson
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

9.  Mammalian 5'-nucleotidases.

Authors:  Vera Bianchi; Jozef Spychala
Journal:  J Biol Chem       Date:  2003-08-28       Impact factor: 5.157

10.  Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE.

Authors:  Javier Torres-Torronteras; Carlo Viscomi; Raquel Cabrera-Pérez; Yolanda Cámara; Ivano Di Meo; Jordi Barquinero; Alberto Auricchio; Giuseppe Pizzorno; Michio Hirano; Massimo Zeviani; Ramon Martí
Journal:  Mol Ther       Date:  2014-01-22       Impact factor: 11.454

View more
  4 in total

1.  The role of dNTP metabolites in control of the embryonic cell cycle.

Authors:  Boyang Liu; Jörg Großhans
Journal:  Cell Cycle       Date:  2019-09-22       Impact factor: 4.534

Review 2.  Nucleotide salvage deficiencies, DNA damage and neurodegeneration.

Authors:  Michael Fasullo; Lauren Endres
Journal:  Int J Mol Sci       Date:  2015-04-27       Impact factor: 5.923

3.  Age-related metabolic changes limit efficacy of deoxynucleoside-based therapy in thymidine kinase 2-deficient mice.

Authors:  Cora Blázquez-Bermejo; David Molina-Granada; Ferran Vila-Julià; Daniel Jiménez-Heis; Xiaoshan Zhou; Javier Torres-Torronteras; Anna Karlsson; Ramon Martí; Yolanda Cámara
Journal:  EBioMedicine       Date:  2019-07-24       Impact factor: 8.143

4.  Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency.

Authors:  Carlos Lopez-Gomez; Maria J Sanchez-Quintero; Eung Jeon Lee; Giulio Kleiner; Saba Tadesse; Jun Xie; Hasan Orhan Akman; Guangping Gao; Michio Hirano
Journal:  Ann Neurol       Date:  2021-08-13       Impact factor: 11.274

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.